Aura Biosciences, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Aura Biosciences, Inc.
Public Company Edition: Entrada’s initial public offering grossed $181.5m while Aura raised $75.6m and Biofrontera brought in $18m. Also, AnaptysBio received $250m in Jemperli royalty deal and 4D Molecular Therapeutics grossed $118.8m in a follow-on offering.
Private Company Edition: The astonishing pace of venture capital investment in drug development continues with another $1.5bn in financings of $100m or more, including $152m for Pyxis and $126m for Omega. New VC funds also continue to launch, including RiverVest’s fifth fund, totaling $275m.
In the latest instalment of VC Playbook, In Vivo gets to know Arix Bioscience, a relatively young venture capital firm that went public in 2016. Arix has “has many similarities yet some key differences from a typical venture capital firm,” says the management team.
Arix Biosciences has unveiled three significant changes to the organization, including the appointment of Christian Schetter as co-managing director, which the healthcare-focused venture capitalist hopes will keep its impressive record of biotech investments on track.
- Site Specific
- Drug Delivery
- Antisense, Oligonucleotides
- Large Molecule
- Nanotechnology, Chips, etc.